Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy. (2nd January 2022)

• Record Type: Journal Article
• Authors: Meskers, Caroline J.W.; Franczak, Marika; Smolenski, Ryszard T.; Giovannetti, Elisa; Peters, Godefridus J.
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 18:Number 1(2022)
• Page Start: 61
• Page End: 83
• Publication Date: 2022-01-02
• Subjects: Pentose phosphate pathway -- glycolysis -- cancer -- NAD/NADH -- chemotherapy; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2022.2049234
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction: The pentose phosphate pathway (PPP) branches from glycolysis and is crucial for cell growth, since it provides necessary compounds for anabolic reactions, nucleotide synthesis, and detoxification of reactive-oxygen-species (ROS). Overexpression of PPP enzymes has been reported in multiple cancer types and linked to therapy resistance, making their inhibition interesting targets for anti-cancer therapies. Areas covered: This review summarizes the extent of PPP upregulation across different cancer types, and the non-metabolic functions that PPP-enzymes might contribute to cancer initiation and maintenance. The effects of PPP-inhibition and their combinations with chemotherapeutics are summarized. We searched the databases provided by the University of Amsterdam to characterize the altered expression of the PPP across different cancer types, and to identify the effects of PPP-inhibition. Expert opinion: It can be concluded that there are synergistic and additive effects of PPP-inhibition and various classes of chemotherapeutics. These effects may be attributed to the increased susceptibility to ROS. However, the toxicity, low efficacy, and off-target effects of PPP-inhibitors make application in clinical practice challenging. Novel inhibitors are currently being developed, which could make PPP-inhibition a potential therapeutic strategy in the future, especially in combination with conventional chemotherapeutics and the inhibition of other metabolic pathways.